The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.
暂无分享,去创建一个
David O Meltzer | M. Chin | D. Meltzer | E. Huang | Elbert S Huang | Marshall H Chin | Lei Jin | Morgan Shook | Lei Jin | Morgan E Shook
[1] M. Weinstein,et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[2] A. Zbrozek,et al. Model of Complications of NIDDM: I. Model construction and assumptions , 1997, Diabetes Care.
[3] S. Kaplan,et al. Foot infections in diabetic patients. Decision and cost-effectiveness analyses. , 1995, JAMA.
[4] A. Zbrozek,et al. Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia , 1997, Diabetes Care.
[5] Volker Foos,et al. The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making , 2004, Current medical research and opinion.
[6] A S Detsky,et al. Primer on Medical Decision Analysis: Part 3—Estimating Probabilities and Utilities , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.
[7] R. Hayward,et al. Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 Diabetes , 1997, Annals of Internal Medicine.
[8] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[9] R. Holman,et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.
[10] C. Cowie,et al. Sociodemographic Characteristics of Persons with Diabetes , 1996 .
[11] Stephen W. Sorensen,et al. The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance , 2005, Annals of Internal Medicine.
[12] D. Singer,et al. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is … or is it? , 1997, The Lancet.
[13] M. Chin,et al. Implications of New Geriatric Diabetes Care Guidelines for the Assessment of Quality of Care in Older Patients , 2006, Medical care.
[14] M. Engelgau,et al. Valuing health-related quality of life in diabetes. , 2002, Diabetes care.
[15] P. Savage,et al. Glucose, Blood Pressure, and Lipid Control in Older People with and without Diabetes Mellitus: The Cardiovascular Health Study , 2002, Journal of the American Geriatrics Society.
[16] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.
[17] Anke Richter,et al. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. , 2002, JAMA.
[18] M. Weinstein,et al. Preference-based measures in economic evaluation in health care. , 2000, Annual review of public health.
[19] D. Singer,et al. Non-insulin-dependent diabetes in older patients. Complications and risk factors. , 1986, The American journal of medicine.
[20] M. Weinberger,et al. Economic impact of diabetes mellitus in the elderly. , 1990, Clinics in geriatric medicine.
[21] Plamen Nikolov,et al. Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.
[22] M. Koopmanschap,et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. , 2002, Diabetes care.
[23] Alastair Gray,et al. Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62) , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.
[24] D. Ronis,et al. BRIEF REPORT: The burden of diabetes therapy , 2005, Journal of General Internal Medicine.
[25] Rury R. Holman,et al. Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .
[26] T. Grist,et al. Magnetic resonance angiography in progressive renal failure: a technology assessment. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.